MBCRPHA@EC2612A

Huaxin Pharmaceutical Subsidiaries Obtain Clinical Trial Approval and Market Approval for New Drugs

Huahuaipuoyi Commerce Completes RMB 3 Billion Medium-Term Note Issuance

Huahuaikang Medicine's Two Drugs Included in National Health Insurance Directory

Huahuaipharma Subsidiary's Pioglitazone Hydrochloride Dispersible Tablets Pass Consistency Evaluation

China Resources Medicine Co., Ltd. Established with a Registered Capital of 30 Million RMB

Shuren Sanjiu Secures Exclusive Rights to Helkos in China

CR Medicine's Five Products Preselected for the 11th National Pharmaceutical Concentrated Procurement

Huamao Pharmaceutical Announces Huansaijiu's Q1-Q3 2025 Performance

China Resources Pharma's ESG rating upgraded to AA

Huaren Medicine's subsidiary obtains certificate for Certrofiban Hydrochloride Sodium Injection

Huaron Medicine Subsidiary Obtains Drug Supplement Approval

Huahuaipu Medicine Subsidiaries Obtain Drug Registration Certificates to Boost Market Competitiveness

BOA Securities Cuts Interim Earnings Forecast and Target Price for China Resources Medicine

CHINARES PHARMA released FY2025 Q1 earnings on August 26, 2025 (BJT) with actual revenue of HKD 70.61 B and EPS of HKD 0.1767

China Resources Medicine Reports Mid-Year Revenue Growth and Profit Decline

CHINARES PHARMA released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue HKD 72.17 B, actual EPS HKD 0.1806

CHINARES PHARMA released FY2025 Semi-Annual Earnings on August 26 Pre-Market BJT, actual revenue HKD 142.78 B (forecast HKD 146.93 B), actual EPS HKD 0.3573 (forecast HKD 0.448)

Huaren Pharmaceutical's Innovative Antibody Drug Development Project Recognized by State-owned Assets Supervision and Administration Commission

CHINARES PHARMA to release FY2025 Semi-Annual earnings on August 26, 2025 (BJT), forecast revenue HKD 146.93 B, EPS HKD 0.448

CR Medicine Co., Ltd Subsidiaries Participate in Establishing Biomedical Investment Fund

MAN SHUN GP

CB GLOBAL

FINSOFT FIN

CH SUPPLY CHAIN

WINSON HLDGS HK

WANJIA GROUP

XI2CSOPMSTR-U

XI2CSOPMSTR

CHINA CHUNLAI

ALLEGRO CULTURE

03320

512290

Beijing launched a pilot program for online diagnosis and treatment services on January 31, starting with three pediatric subspecialties at Beijing Children's Hospital and Capital Institute of Pediatrics. This service provides online pre-consultation, online diagnosis and treatment, and medication delivery for first-time patients, aiming to ensure the safety and quality of diagnosis and treatment. Doctors can complete the initial diagnosis and issue prescriptions via the internet

Wallstreetcn

E Fund CSI 300 Health Care ETF

SINOPHARM

CHINARES PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI All Share Health Care Devices ETF

Shanghai Pharma

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Guotai CSI Bio-medicine ETF

ALI HEALTH

JD HEALTH

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

PA GOODDOCTOR

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI All Share Health Care ETF

SH PHARMA

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal 800 Health Care ETF

SINOPHARM(CNCM LTD)

Ping An CSI Medicine and Medical Device Innovation ETF

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

589720

588250

588130

CR Boya Bio-pharmaceutical, an affiliate of China Resources Pharmaceutical Group Ltd., anticipates a 10% to 25% increase in operating revenue for the year ending December 31, 2025, due to the acquisition of Green Cross HK Holdings Limited. However, the net profit attributable to shareholders is expected to decline significantly, primarily due to a downturn in the hyaluronic acid market and impairments of approximately RMB300 million related to intangible assets and goodwill following the acquisition. The company is listed on the Shenzhen Stock Exchange.

Reuters

Guotai SSE STAR Brand Name Drug ETF

Penghua SSE STAR Biology and Medicine ETF

BOYA BIOLOGY

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn

China Resources Double-Crane Pharmaceutical Co., Ltd., an affiliate of China Resources Pharmaceutical Group Ltd., has received approval from the China Securities Regulatory Commission to issue corporate bonds worth RMB3 billion. The approval is valid for 24 months, allowing the company to issue the bonds in tranches.

Yinhua CSI Research Sector 100 ETF

Yinhua CSI Innovative Drugs Industry ETF

CR Double-Crane

CR Double-Crane, an Affiliate of China Resources Pharmaceutical, Wins Approval to Issue RMB3 Billion Corporate Bonds

China Resources Jiangzhong Pharmaceutical Co., Ltd. reported a 16.6% growth in operating profit for 2025, with total operating revenue of RMB 4.2195 billion and an operating profit of RMB 1.1985 billion. The net profit attributable to shareholders was RMB 906.12 million. Jiangzhong Pharmaceutical is a subsidiary of China Resources Pharmaceutical Group Ltd., which holds a 26.12% interest in the company. The financial information is based on unaudited preliminary results for the year ended December 31, 2025.

Jiangzhong Pharmaceutical Affiliate Posts 16.6% Operating Profit Growth for 2025

600750

China Resources Pharma announced that its subsidiary China Resources Jiangzhong achieved a total operating revenue of RMB 4.22 billion for the fiscal year 2025, a year-on-year decrease of 4.9%. The net profit attributable to shareholders was RMB 906 million, an increase of 15%, with earnings per share of RMB 1.43

AASTOCKS

China Resources Jiangzhong

China Resources Pharma's subsidiary China Resources Jiangzhong earned 906 million RMB last year, an increase of 15%

China Resources Pharmaceutical Group Ltd. has scheduled its first extraordinary general meeting for February 6, 2026, in Beijing. Shareholders will vote on a new Sales Framework Agreement for 2026-2028 and a special resolution to adopt new Articles of Association, potentially updating the company's governance framework. The current analyst rating for the stock (HK:3320) is a Hold with a price target of HK$5.00. The company operates in the pharmaceutical sector in mainland China, with a market cap of HK$28.52B and a year-to-date price performance of 2.02%.

Tip Ranks

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua CSI HK Connect Health Care Composite ETF

China Resources Pharmaceutical Calls 2026 EGM to Approve Sales Framework and New Articles

CHINARES PHARMA announced that its subsidiary Runsheng Pharmaceutical's salmeterol/fluticasone inhalation powder has received marketing approval from the U.S. Food and Drug Administration (FDA), marking the first time the FDA has approved an inhalation powder developed independently by a Chinese pharmaceutical company. The salmeterol/fluticasone inhalation powder is used in a combination therapy (bronchodilator and inhaled corticosteroid) for the regular treatment of reversible obstructive airway diseases, including asthma in adults and children

CHINARES PHARMA's asthma inhalation powder has been approved by the FDA for market launch

China Resources Pharmaceutical (3320.HK) has recently seen its stock price continue to decline, but the pace of the drop has gradually slowed, with short-term declines tending to converge. The daily MACD remains in a bearish crossover, but the green bars show signs of narrowing, indicating a marginal weakening of bearish strength. Currently, the K-line trend is stabilizing in a low range, with capital outflows slowing down, and some bottom-fishing funds are beginning to tentatively position themselves. In terms of the company's fundamentals, the pharmaceutical industry is under overall pressure, with rapid sector rotation. However, some policy support and progress in innovative businesses provide certain imaginative space for the future market. If there are favorable industry developments or catalysts such as the approval of innovative drugs or new products at the company level, the stock price may experience a rapid recovery. From a technical perspective, a phase bottom is currently being constructed. If it can effectively break through the pressure of the 5-day and 10-day moving averages, along with increased trading volume, it may be seen as a reversal signal. Overall, it is necessary to observe whether bullish momentum continues to strengthen. Operational advice suggests gradually accumulating at low levels, paying attention to changes in trading volume and news catalysts. If it continues to operate weakly in the future, a quick in-and-out strategy should be adopted, maintaining a flexible trading strategy to manage risk effectively

Technical Forecast

Morning Trend | CHINARES PHARMA's decline at low levels slows down, can news catalysts reverse the situation?

CHINARES PHARMA announced that its subsidiary Beijing Shuanghe Runchuang Technology's DC6001 tablets have received clinical trial approval from the National Medical Products Administration for the treatment of hereditary macular degeneration in adolescents. At the same time, the metronidazole gel of China Resources Sanjiu Pharmaceutical Co., Ltd. has been approved for market launch, suitable for local treatment of various skin inflammations

CHINARES PHARMA's DC6001 tablets and metronidazole gel approved for clinical use and market launch

CHINARES PHARMA announced that its Yiqi Qingfei Granules and Methylphenidate Hydrochloride Sustained-Release Capsules have been included in the recently released "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)." Yiqi Qingfei Granules are specifically aimed at the comprehensive symptoms during the recovery period of various respiratory infection diseases. Methylphenidate Hydrochloride Sustained-Release Capsules are used for the treatment of Attention Deficit Hyperactivity Disorder in children aged 6 and above. Both products were approved for market launch in January of this year

Two products under CHINARES PHARMA have been included in the national medical insurance catalog

Yesterday, China Resources Pharmaceutical (3320.HK) maintained a low-volume oscillating trend, with the stock price gradually dipping towards the 30-day moving average. Pharmaceutical stocks have recently been in a weak range, with overall capital showing an outflow pattern, and defensive allocation preferences dominating. As the national medical insurance negotiation phase approaches, there is a lack of significant positive news, and some major players are choosing to remain inactive or reduce holdings in advance, leading to a spread of wait-and-see sentiment. 

From a technical perspective, the MACD daily structure has shown a clear death cross, with short-term momentum leaning bearish. The 5-day and 10-day moving averages are stuck in a stalemate, indicating weak bullish momentum and a slight advantage for the bears. Throughout the day, net capital flow slightly outflowed, further indicating that major players have no intention of deep involvement in the short term. Considering the strong sensitivity of the pharmaceutical sector to news, future events such as medical insurance price adjustments and generic drug bidding may become important catalysts for short-term breakthroughs, which need to be closely monitored. 

Currently, China Resources Pharmaceutical maintains a box oscillation pattern. If there are clear policy developments or if the pharmaceutical sector shows new incremental movements, it could become a point for right-side capital to test new actions. However, the operational nodes remain unclear, and the sector carries significant risks; any blind chasing of price increases can easily increase risk exposure. There are high requirements for position management, and close attention should be paid to intraday trading and position changes, adjusting response strategies in conjunction with policy signals. 

In summary, although China Resources Pharmaceutical is under short-term pressure, the adjustment range is gradually approaching a relatively supportive area

Morning Trend | CHINARES PHARMA consolidates with reduced volume, is a breakout imminent?

CHINARES PHARMA announced that its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for Pioglitazone Hydrochloride Dispersible Tablets, which is regarded as passing the consistency evaluation. Pioglitazone Hydrochloride Dispersible Tablets are used for the treatment of type 2 diabetes

CHINARES PHARMA announced that its Type 2 diabetes drug has received a notice of approval for a supplemental drug application

000999

China Resources Pharmaceutical announced that its subsidiary, CR Sanjiu, has obtained implied permission for clinical trials of its pediatric calming and brain-nourishing granules. This product was jointly developed by CR Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a Category 1.1 new drug in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied permission for clinical trials will help further enrich its product line and enhance the market competitiveness of its products

CR Sanjiu

CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials

CHINARES PHARMA announced that five of its products are expected to be selected for the 11th batch of national centralized drug procurement, covering multiple fields such as cardiovascular and nervous systems. The selected products include Methochlorpromazine Hydrochloride Injection and Meprobamate Injection, among others. This centralized procurement will prioritize the use of selected drugs, which will help enhance market share and brand influence, positively impacting future operating performance

CHINARES PHARMA: 5 products under its umbrella are expected to be selected for the 11th batch of national drug procurement

MBCRPHA@EC2612A(18720.HK)

This afternoon, appointment reservations opened for the pilot program of internet diagnosis and treatment in Beijing

CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn

CR Double-Crane, an Affiliate of China Resources Pharmaceutical, Wins Approval to Issue RMB3 Billion Corporate Bonds

Jiangzhong Pharmaceutical Affiliate Posts 16.6% Operating Profit Growth for 2025

China Resources Pharma's subsidiary China Resources Jiangzhong earned 906 million RMB last year, an increase of 15%